HPTN 083

Cabotegravir for HIV Prevention in MSM and Transgender Women

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 4,566 cisgender MSM and transgender women at high risk of HIV, long-acting injectable cabotegravir every 8 weeks reduced HIV acquisition compared with daily oral TDF/FTC.

4 566

Schéma

Double-blind, double-dummy RCT

Critère

Incident HIV infection

Pertinence

RésultatIncidence 0.41 vs 1.22 per 100 person-years; HR 0.34 — 66 % more effective.

Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608. 10.1056/NEJMoa2101016

Discussion et critique

Basis of the FDA approval of long-acting cabotegravir for PrEP — particularly impactful for populations with adherence challenges.